Trial site
Onco Clinic Consult S.A.
Craiova, 200508, RomaniaEU-13 widening countryNot linked to an institution yet
- 9running trials
- 6closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 39 trials
- Phase 2/34 trials
- Phase 22 trials
- Status
- Completed6 trials
- Active, not recruiting5 trials
- Recruiting3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Celcuity Inc2 trials
- H e x a l AG2 trials
- BioNTech SE1 trial
- Bristol-Myers Squibb1 trial
- Daiichi Sankyo1 trial
- and 8 more
Running trials
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615· Phase 2· Shanghai Henlius Biotech· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)
2024-513160-25-00· Phase 3· H e x a l AG· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831· Phase 2/3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Celcuity Inc· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error